Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"siRNA therapeutics"”.
-
Development of Targeted siRNA Therapeutics for Triple Negative Breast Cancer and Liver Fibrosis
… systems to deliver small interfering RNA (siRNA) for the treatment of triple negative breast cancer (TNBC) and liver fibrosis. siRNAs targeting vascular endothelial growth factor (VEGF) and IκB kinase ε (IKBKE) were used for treating TNBC, while siRNA targeting poly(rC) binding protein 2 …
-
Mouse Models of Inherited Skin Diseases
… mutant KRT9 allele with short interfering RNAs (siRNAs) was explored as a potential therapeutic approach. This led to the development and in vitro validation of potent mutation- and gene-specific siRNA inhibitors. <br/>Despite its importance in EPPK, little is known about the physical requirement …
-
Tumor-penetrating delivery of small interfering RNA therapeutics
… "delivery" challenge, as small interfering RNA (siRNA) therapeutics must overcome clearance mechanisms and penetrate into tumor tissues to access cancer cells. This thesis sought to develop nanotechnology-based platforms to rapidly discover and validate cancer targets in vivo. First, we developed …
-
Multifunctional Chemical Cross-linkers for Drug Carriers and Molecular Probes
… vesicles and quantify endosomal escape for siRNA therapeutics. Taken together, these works highlight the importance of chemical cross-linkers in the design of multifunctional bioconjugates for a variety of applications.
-
Development and characterization of chemical modifications for siRNA strand selection
Small interfering RNA (siRNA) are non-coding, double-stranded RNA that enable efficient gene silencing through RNA interference (RNAi) mechanisms. The primary effector of RNAi is an RNA-guided nuclease, Ago2, which selects one of the two strands as a guide to form the RNA induced silencing complex …
-
Engineering multimodal nanoparticles to combat triple-negative breast cancer
… compared to other subtypes. Many current chemotherapeutics used to treat TNBC are nonspecific, and, therefore, cause off-target effects and fail to elicit a robust tumor response, which results in higher mortality and recurrence rates. Targeted therapy enabled by nanoparticle (NP)-based drug …
-
RNA Therapeutics for Fibrolamellar Hepatocellular Carcinoma
… to synthesize small interfering RNAs (siRNAs) with state-of-the-art chemical modifications. Multiple siRNA therapeutics targeting genes in the liver have been FDA approved. The majority of these use a carbohydrate group, GalNAc, that binds to the asialoglycoprotein receptor (ASGR), …